Xiaoliang Zhuo

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (Belgium)

发表论文 51 篇 · 总被引 1800 次 · h-index 21

代表论文

• Metabolic and Pharmaceutical Aspects of Fluorinated Compounds (2020 · Journal of Medicinal Chemistry · 被引 710)
• Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies (2017 · Journal of Medicinal Chemistry · 被引 31)
• Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor (2017 · ACS Medicinal Chemistry Letters · 被引 28)
• Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481 (2019 · ACS Medicinal Chemistry Letters · 被引 23)
• Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis (2022 · Journal of Medicinal Chemistry · 被引 22)
• The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase (2017 · MedChemComm · 被引 18)